Additional years to extend the agreement

No definition available.

Name:	regn_Additionalyearstoextendtheagreement
Namespace Prefix:	regn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of non-refundable payment received in relation to the collaboration agreement. May be an up-front payment, termination payment, and/or payment made in connection to an amendment to the agreement.

+ References

No definition available.

+ Details

Name:	regn_Amountofnonrefundablepaymentreceivedforcollaborationagreement
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of non-refundable up-front payment the Company will receive in relation to the IO collaboration.

+ References

No definition available.

+ Details

Name:	regn_Amountofnonrefundablepaymentwillreceiveforcollaborationagreement
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The maximum annual amount of funding for research activities through 2017 per the amended agreement.

+ References

No definition available.

+ Details

Name:	regn_AnnualFundingMaximumOfResearchActivitiesPerAmendedAgreement
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The excess percentage of profits from collaboration not required to be used to reimburse development cost in any calendar quarter.

+ References

No definition available.

+ Details

Name:	regn_ExcessShareOfProfitNotRequiredToToBeAppliedToReimburseDevelopmentCost
Namespace Prefix:	regn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The maximum amount of cost reimbursement the Company will receive, subject to certain annual limits.

+ References

No definition available.

+ Details

Name:	regn_FundingMaximumofResearchActivitiesPerAgreement
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Aggregate amount of twelve month sales upon which sales milestone would be received.

+ References

No definition available.

+ Details

Name:	regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Potential agreement term, from the effective date of agreement.

+ References

No definition available.

+ Details

Name:	regn_Licenseagreementterm
Namespace Prefix:	regn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The maximum amount of sales milestone payments the Company is eligible to receive when and if total annual sales achieve certain specified levels.

+ References

No definition available.

+ Details

Name:	regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The maximum amount of shared development expenses for PD-1.

+ References

No definition available.

+ Details

Name:	regn_Maximumamountofshareddevelopmentcosts
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Our share of profits/losses related to commercialization of products by our collaborator based on sales outside the United States. Under the terms of our collaboration agreement, we share profits/losses with our collaborator on commercialization of products.

+ References

No definition available.

+ Details

Name:	regn_Netprofitlossfromcommercializationofproductsundercollaborationagreement
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of Payments

+ References

No definition available.

+ Details

Name:	regn_NumberofPaymentstheCompanymade
Namespace Prefix:	regn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of development milestone payments the Company received

+ References

No definition available.

+ Details

Name:	regn_NumberofdevelopmentmilestonepaymentstheCompanyreceived
Namespace Prefix:	regn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of subsequent Shared Phase 3 Trial costs borne by the collaborating party upon receipt of the first positive Phase 3 trial results for a co-developed drug candidate.

+ References

No definition available.

+ Details

Name:	regn_PercentageOfTrialCostsBorneByCollaboratingParty
Namespace Prefix:	regn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of subsequent Shared Phase 3 Trial costs borne by the Company upon receipt of the first positive Phase 3 trial results for a co-developed drug candidate.

+ References

No definition available.

+ Details

Name:	regn_PercentageOfTrialCostsBorneByEntity
Namespace Prefix:	regn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of aggregate net sales to be paid by the related party in such calendar year.

+ References

No definition available.

+ Details

Name:	regn_Percentageofaggregatenetsalestobepaidbytherelatedpartyinsuchcalendaryear
Namespace Prefix:	regn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of development cost for the territory outside the United States previously required to be paid for under the collaboration.

+ References

No definition available.

+ Details

Name:	regn_PercentageofdevelopmentcostfortheterritoryoutsidetheUnitedStatespreviouslyrequiredtobepaidforunderthecollaboration
Namespace Prefix:	regn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Period for Achieving Sales Target for Milestone Payment, Rolling Basis

+ References

No definition available.

+ Details

Name:	regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
Namespace Prefix:	regn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The period of notice (in months) for either party under the agreement to opt-out of further development and/or commercialization of each antibody product which enters development.

+ References

No definition available.

+ Details

Name:	regn_PeriodOfNoticeToOptOutOfFurtherDevelopmentAndOrCommercialization
Namespace Prefix:	regn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The total potential amount of research and development expenses the Company may pay to identify and validate potential immuno-oncology targets and develop therapeutic antibodies against such targets through clinical proof-of-concept.

+ References

No definition available.

+ Details

Name:	regn_PotentialfutureRDexpenses
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The maximum amount of development milestone payments the Company may pay.

+ References

No definition available.

+ Details

Name:	regn_Potentialfuturemilestonepayments
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Reduction of Funding for Research Activities Per Agreement

+ References

No definition available.

+ Details

Name:	regn_ReductionofFundingforResearchActivitiesPerAgreement
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.

+ References

+ Details

Name:	us-gaap_ContractsRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of other research and development expense.

+ References

+ Details

Name:	us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

-Subsection 1

+ Details

Name:	us-gaap_RecognitionOfDeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Related Parties

-URI http://asc.fasb.org/extlink&oid=16382449

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.6-07.1(c))

-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

+ Details

Name:	us-gaap_RevenueFromRelatedParties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis=regn_AfliberceptAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis=regn_AntibodyCollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis=regn_PDGFMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis=regn_IODiscoveryAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis=regn_IOLicenseandCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=regn_PD1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=regn_NewFundingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=regn_PreviousFundingunderAntibodyDiscoveryAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=regn_Salesachievement600millionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=regn_Salesachievement500millionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=regn_Salesachievement700millionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=regn_PDGFMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=regn_PraluentandsarilumabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements (Sanofi) (Details) $ in Thousands	1 Months Ended		3 Months Ended				6 Months Ended		12 Months Ended
Collaboration Agreements (Sanofi) (Details) $ in Thousands	Jul. 31, 2015 USD ($)	Nov. 30, 2009 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Collaboration Agreement [Line Items]
Licenses Revenue			$ 11,451		$ 7,788		$ 39,288	$ 15,330
Period for Achieving Sales Target for Milestone Payment, Rolling Basis				12 months				12 months
Revenue from Related Parties			195,110		142,595		368,466	$ 273,103
Research and development			390,330		294,501		$ 733,443	581,880
ZALTRAP Agreement
Collaboration Agreement [Line Items]
Percentage of repayment of development balance out of profits							50.00%
Deferred Revenue, Revenue Recognized				$ 14,900
Licenses Revenue			3,200				$ 23,000
Net profit (loss) from commercialization of products under collaboration agreement			0		(692)		0	(3,904)
Reimbursement of Regeneron research and development expenses			0		1,338		686	2,430
Contracts Revenue			0		1,484		15,236	3,661
Revenue from Related Parties			0		2,130		15,922	2,187
Antibody Collaboration
Collaboration Agreement [Line Items]
Net profit (loss) from commercialization of products under collaboration agreement			(46,313)		(4,295)		(68,718)	(4,295)
Recognition of Deferred Revenue			2,560		2,560		5,121	5,121
Annual funding maximum of research activities per amended agreement		$ 160,000							$ 130,000	$ 130,000	$ 145,000
Reduction of Funding for Research Activities Per Agreement	$ 75,000
Reimbursement of Regeneron research and development expenses			211,516		137,893		380,336	264,715
Contracts Revenue			27,347		4,307		35,805	5,375
Revenue from Related Parties			$ 195,110		140,465		$ 352,544	270,916
Percentage of Trial Costs borne by collaborating party							80.00%
Percentage of Trial Costs borne by entity							20.00%
Research and development							$ 47,500	52,900
Minimum IO Discovery Agreement Term	3 years
PDGF
Collaboration Agreement [Line Items]
Number of Payments the Company made			1			2
Other Research and Development Expense			$ 10,000			$ 5,000
Milestone payment							$ 20,000
IO Discovery Agreement
Collaboration Agreement [Line Items]
Amount of non refundable payment will receive for collaboration agreement	$ 265,000
Potential future R&D expenses	1,090,000
Funding Maximum of Research Activities Per Agreement	$ 825,000
Minimum IO Discovery Agreement Term	5 years
Additional years to extend the agreement	3 years
Excess Share of profit not required to to be applied to reimburse development cost	10.00%
IO License and Collaboration Agreement
Collaboration Agreement [Line Items]
Amount of non refundable payment will receive for collaboration agreement	$ 375,000
Excess Share of profit not required to to be applied to reimburse development cost	10.00%
Period of Notice to Opt Out of Further Development and or Commercialization	12 months
IO License and Collaboration Agreement \| PD-1
Collaboration Agreement [Line Items]
Maximum amount of sales milestone payments if total sales achieve specific levels	$ 375,000
Levels of twelve month sales at which sales milestone payments would be received	$ 2,000,000
Period for Achieving Sales Target for Milestone Payment, Rolling Basis	12 months
Maximum amount of shared development costs	$ 650,000
Minimum [Member] \| ZALTRAP Agreement
Collaboration Agreement [Line Items]
Percentage of net sales paid by the related party							15.00%
Maximum [Member] \| ZALTRAP Agreement
Collaboration Agreement [Line Items]
Percentage of net sales paid by the related party							30.00%
New Funding \| IO Discovery Agreement
Collaboration Agreement [Line Items]
Funding Maximum of Research Activities Per Agreement	750,000
Previous Funding under Antibody Discovery Agreement \| IO Discovery Agreement
Collaboration Agreement [Line Items]
Funding Maximum of Research Activities Per Agreement	$ 75,000
sales achievement - $600 million
Collaboration Agreement [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized								15,000
sales achievement - $500 million
Collaboration Agreement [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized								15,000
sales achievement - $700 million
Collaboration Agreement [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized								$ 15,000
PDGF
Collaboration Agreement [Line Items]
Number of development milestone payments the Company received			1			2
Percentage of repayment of development balance out of profits							50.00%
Amount of non refundable payment received for collaboration agreement						$ 25,500
Revenue Recognition, Milestone Method, Revenue Recognized			$ 5,000
Praluent and sarilumab [Member] \| Antibody Collaboration
Collaboration Agreement [Line Items]
Research and development			$ 22,500		$ 29,100